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Summary: We determined the trough blood and plasma concentrations of tac-
rolimus from the day of transplantation through 30 days posttransplantation in 
four liver and four kidney transplant patients by three different methods. The 
first method involved a solid phase extraction of the blood or plasma using 
Sep-Pak columns tSPs) followed by quantitation of tacrolimus using an en-
zyme-linked immunosorbent assay (ELISA): the second method involved a 
liquid-liquid extraction using methylene chloride (MC) followed by quantita-
tion of tacrolimus using the ELISA. and the third method involved a high-
performance liquid chromatography (HPLC) fractionation of the extract ob-
tained from the solid-phase extraction and quantitation of tacrolimus in the 
fractions by ELISA. The trough plasma tacrolimus concentrations ranged from 
0.1 to 5.2 nglm\. While the trough plasma concentrations of tacrolimus were 
similar and independent of the method of analysis in kidney transplant patients 
and in liver transplant patients with normal biochemical protile. in patients 
with liver dysfunction. tacrolimus plasma concentrations were higher when 
measured by SP·ELISA and MC·ELISA methods as compared to the HPLC-
ELISA method. In plasma samples obtained from liver transplant patients with 
liver dysfunction. the presence of some metabolites that cross-reacted with the 
antibody used In the ELISA could be documented in the HPLC fraction cor-
responding to the metabolites. This indicates that while tacrolimus metabolites 
that cross-react significantly with the antibody used in the ELISA do not 
accumulate in kidney transplant patients. they can appear In the plasma of 
patients with liver dysfunction. The trough blood tacrolimus concentrations in 
patients were signiticantly higher than the corresponding plasma concentra-
tions and ranged from 1.4 to 107 ng/ml. The trough blood tacrolimus concen· 
trations were similar and independent of the method of analysis in kidney and 
liver transplant patients. suggesting unchanged tacrolimus to be the maJor 
component in the blood. The HPLC fractions corresponding to the metabolites 
of tacrolimus did not contain any components that cross-reacted with the an-
tibody used. This study documents that the methods used in this study for the 
analysis of blood concentrations of tacrolimus appear to be specitic for the 
parent tacrolimus and can be used in future pharmacokinetic and clinical stud-
ies. Key Words: Analysis-immunosuppression-Tacrolimus-Therapeulic 
monitoring. 
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Therapeutic monitoring of immunosuppressive 
drugs is an integral part of optimizing drug therapy 
in transplant patients because of the narrow thera-
peutic index of these agents. Since immunosuppres-
sive drugs are used on a long-term basis. trough 
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blood or plasma concentration measurement of im-
munosuppressive drugs in organ transplant patients 
will also help in assuring compliance with the drug 
treatment protocol. Tacrolimus. a recently ap-
proved immunosuppressive drug, is effective in pre-
venting graft rejection in patients after liver. kid-
ney, and heart transplantation (I). Large interindi-
vidual variability in the pharmacokinetics (2) and 
the nephrotoxicity of tacrolimus (3) necessitates 
routine monitoring of this agent in transplant pa-
tients. Tacrolimus has been measured in plasma by 
an enzyme-linked immunosorbent assay (ELISA) 
that was originally developed by Tamura et al. (4), 
or by a modification of this ELISA (5-8). or by 
high-pressure liquid chromatography (HPLC)-
ELISA (9.10), or by HPLC after derivatizing with 
danzyl hydrazine (II). or by a bioassay (12). Blood 
concentration of tacrolimus has been measured by 
ELISA (6.7.8.13), by a microparticle enzyme im-
munoassay developed by Abbott Laboratories (14-
16), by a radioreceptor assay (17). or by HPLC-
mass spectrometry (18.19). 
Recently, we compared the plasma tacrolimus 
concentrations in kidney and liver transplant pa-
tients as measured by ELISA after a solid-phase 
extraction or a liquid-liquid extraction using meth-
ylene chloride or after a solid-phase extraction and 
HPLC fractionation to separate unchanged tacroli-
mus from metabolites that might be coextracted 
(10). We observed significant differences in the 
plasma concentration of tacrolimus between the dif-
ferent methods used only in samples obtained from 
patients with impaired liver function as determined 
by elevated bilirubin concentrations. This study 
was designed to extend our observations to whole 
blood tacrolimus concentration measurements in 
liver and kidney transplant patients during the im-
mediate postoperative period. 
MATERIALS AND METHODS 
Materials 
Tacrolimus pure drug. the monoclonal antibody 
for tacrolimus, and tacrolimus peroxidase enzyme 
conjugate were supplied by Fujisawa Pharmaceuti-
cals. Osaka. Japan. Anti-mouse IgG was purchased 
from Atlantic Antibodies (Stillwater. MN. U.S.A.)' 
Sep-Pak columns (SPs) (C-18) were obtained from 
Waters (Milford. MA. U.S.A.). O-Phenylenedi-
amine was purchased from Sigma (St. Louis. MO. 
U .S.A.I. Methylene chloride and methanol were 
Ih", D"'ff !.fun;,. ~D"fI 17, No, 2./995 
purchased from Fisher Scientific (Pittsburgh, PA. 
U.S.A.). The HPLC column used. a u-Bondapak 
C-18 column that is 15 cm long with an internal 
diameter of 3.9 mm was maintained at 60°C and the 
column eluents were monitored at 214 nM. Using a 
mobile phase of 80% methanol and 20% water (acid-
ified to pH 6 with HCn at a flow rate of 1.5 ml/min. 
the retention time of tacrolimus was 4.8 min. 
Methods 
Clinical Protocol 
Patients received i. v. tacrolimus <0.1 mg/kg/day) 
as a continuous i. v. infusion during the immediate 
postoperative period and for up to 3-7 days after 
surgery. Oral therapy was initiated as soon as the 
patients were able to tolerate oral intake. Tacroli-
mus (0. \-0.24 mg/kg/day) was administered orally 
twice daily. MUltiple serial blood samples were col-
lected in heparinized tubes prior to the morning 
dose of tacrolimus from four liver and four kidney 
transplant patients from day I after surgery until 
approximately 30 days posttransplantation. 
Analysis 
Aliquots of the whole blood samples were sepa-
rated and maintained at 4°C until analysis. The rest 
of the blood samples were incubated at 3rC for 45 
min and centrifuged at 37°C for 10 min and the 
plasma obtained was analyzed on the same day or 
frozen at - 20°C until analysis. The calibration 
curve for whole blood consisted of blank blood 
samples spiked with tacrolimus concentrations of 0, 
O.K. 4. K, 16. 40. and 64 ng/ml. Blood and plasma 
samples were extracted by the solid-phase extrac-
tion method. or by the liquid-liquid extraction 
method using methylene chloride. as described pre-
viously (10). except for the use of 1.0 N of HCI to 
assure complete lysis of whole blood samples prior 
to extraction. Additional samples were also ex-
tracted by the solid-phase extraction method and 
subjected to HPLC separation (as described in ref-
erence 10). and the fractions corresponding to the 
intact tacrolimus (fraction 2. 3.6-{-, min) and tacroli-
mus-related materials (fraction I. 0-3.6 min) were 
separately collected and evaporated to dryness un-
der nitrogen. All the extracts were analyzed by 
ELISA. with overnight incubation. 
A minimum of nine blood and plasma samples 
was analyzed from each of the patients observed. 
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Biochemical parameters indicative of the kidney 
function (serum creatinine level) and liver function 
(bilirubin and aspartate and alanine aminotrans-
ferase levels) were also measured in these patients 
over the entire study period. 
RESULTS 
The biochemical profiles of the patients observed 
are listed in Table I. While all but one kidney trans-
plant patient had normal liver function test results. 
not all the liver transplant patients had normal kid-
ney function throughout the entire course of study. 
The interday coefficients of variation of the three 
methods used varied from 4.2 to 19.7% (Table 2). 
and were similar between the three methods used. 
Figures I and 2 illustrate tacrolimus blood con-
centrations as measured by the three methods in 
liver and kidney transplant patients. respectively. 
[n all the patients. the whole blood concentration of 
tacrolimus was very similar as measured by ELISA 
after the three different extraction/separation pro-
cedures. The regression equations of the tacrolimus 
concentrations measured by HPLC-ELISA versus 
SP-ELISA or MC-ELISA in whole blood are listed 
in Table 3. There was a significant correlation 
(0.821-0.949) between the two variables evaluated. 
and the slope of the lines was near unity (0.92-1.1), 
Figures 3 and 4 illustrate the plasma concentra-
tions of tacrolimus in liver and kidney transplant 
patients as measured by the three methods. Tacroli-
mus plasma concentrations were similar as mea-
sured by the three methods in the kidney transplant 
patients at all times. However. in the liver trans-
plant patients. when the serum bilirubin concentra-
tions were elevated. the tacrolimus concentrations 
TABLE 2. Between-run precision of different 
assay methods 
Whole blood Plasma 
Mean. Mean. 
nglml %CV No. nglml %CV No. 
Solid-phase 
extraction 
LC 13.2 18.2 7 0.7 14.2 18 
MedC 23.4 19.7 7 2.2 \3.6 18 
HC 36.3 15.4 7 5.8 12.0 18 
Methylene 
chloride 
extraction 
LC 11.1 5.4 7 0.6 16.6 8 
MedC 18.5 8.0 7 1.8 11.1 6 
HC 30.6 13.0 7 5.7 15.7 5 
HPLC 
LC 15.5 13.5 3 0.7 14.3 7 
MedC 28.9 ·U 3 2.3 17.4 7 
HC 35.1 5.4 4 5.6 10.7 7 
CV. coefficient of variation: Le. low control: MedC. medium 
control: He. high control: HPLe. high-performance liquid chro-
matograph y . 
measured by SP-ELISA and MC-ELISA were 
higher than the values obtained by the HPLC-
ELISA method. As the bilirubin concentrations re-
covered toward normal values. the concentration of 
tacrolimus measured by all three methods was al-
most identical. Correspondingly. Table 3 shows a 
slope of greater than unity (1.87 and 1.75, respec-
tively) when plasma tacrolimus concentrations 
measured by SP-ELISA or MC-ELISA were com-
pared with HPLC-ELISA measurements. 
Figure 5 illustrates the correlation between 
plasma concentrations and whole blood concentra-
tions in liver and kidney transplant patients as mea-
sured by all three methods. Blood and plasma con-
TABLE 1. Biochemical prrlfi/e ill f{lIIr lil'C'f alld filllr kidllev transplant pati('l/t.t 
Creatinine. mgldl Bilirubin. mgldl AST. lUlL ALT. lUlL 
Immediate 3 wk Immediate J wk Immediate J wk Immediate 3 wk 
postoperative after postoperative after postoperative after postoperative after 
Patients period transplant penod transplant penod transplant penod transptant 
Kidney 
CK 3.6 1.7 11,4 11.3 "6 ~l JK 66 
KW 1.2 1.2 0.9 0.7 712 33 1.-'76 89 
JG 0.8 2.9 II.S O.K 46 18 34 42 
PC 2.3 ' , 11.7 D.6 ~l -'4 27 140 
Liver 
RC 4.1 3.3 X.O ~K9 101 90 93 96 
US Z.7 4.4 8.5 1.6 6.605 ~4 'J% 31 
IZ Z.4 1.4 13.4 1"-3 I.Z47 91 644 127 
LT 1.6 1.3 14.5 ~SKP 863 136 ns 495 
AST. aspanate aminotranSferase: ALT. alanine ammotransferase. 
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FIG. 1. Whole·blood FK S06 concentrations as measured by Sep·Pak enzyme-linked immunosorbent assay (ELISA) (triangles). meth· 
ylene chloride ELISA (black boxes). high-pertormance liquid chromatography ELISA (circles). and bilirubin (white boxes) in four liver 
transplant patients. 
centrations were poorly correlated (r ~ 0.59) with 
each other. The overall slope of blood versus 
plasma concentrations (4.1) in liver transplant pa-
tients was lower than the corresponding overall 
slope (11.7) in the kidney transplant patients (Table 
4). The slope of the line comparing the plasma 
HPLC·ELISA concentrations versus whole blood 
HPLC-ELISA concentrations in liver transplant pa-
tients was also lower than the corresponding slope 
in the kidney transplant patients. The tacrolimus 
equivalent in fraction I (corresponding to HPLC 
fraction collected from 0 to 3.6 min) was <O.H ngiml 
in all cases. 
DISCUSSION 
In this study we compared three methods of mea· 
suring tacrolimus concentrations in plasma and 
whole blood. The sensitivity and the interday vari-
ations of the three methods were comparable and 
were acceptable for routine clinical use. 
Over the past few years we have been using the 
SP extraction procedure for measuring plasma con· 
qlf~D O,ul/ Mom'. ~·"fK 17. No.1. 1995 
centrations of tacrolimus in transplant patients. In a 
recent publication (10) we reported our observation 
of identical tacrolimus concentrations in plasma as 
measured by SP·ELISA. MC·ELISA. and HPLC· 
ELISA in kidney transplant patients and in liver 
transplant patients with biochemical protiles indic· 
ative of normal liver function. In patients with abo 
normal liver function. as determined by serum bil-
irubin concentrations >2 mgidl. the SP·ELISA 
method tends to give higher estimates of tacrolimus 
concentration in comparison to the MC·ELISA 
method. However. both of these methods give val· 
ues that are higher lslope of Sp·ELISA vs. HPLC· 
ELISA was 1.53 (n = 40), vs. slope of Me· ELISA 
vs. HPLC-ELISA. 1.13 (n = 40)) than the HPLC-
ELISA method. which measures only the parent 
tacrolimus in plasma. This is believed to be the reo 
suit of coelution of some tacrolimus metabolites in 
the SP and MC extraction that cross·react with the 
antibody used in the ELISA procedure. When data 
from patients with a serum bilirubin concentration 
of <2 mgldl were analyzed. the slope of the SP· 
ELISA versus HPLC·ELISA was 1.19 (n = 27), 
164 V. WARTY ET AL. 
PATENTRe 
____________ P-_--______________ ~ 
,35 
5 l- '- - - - - -.,- - - Y, - _, , ;; 
• :30 t 
-S4 .... ---.----"--,-- KOR~ 
~ 3 L - " _. - :!. - - - . - - - .. -' - - . - - - - ~ 20 ~ ! ; e- • '. ;.>-- 4 :J 
f 2 J- _ t ~ _ ._ _ ______ ~ _ ~ 15 : 
I D~_-D~_4 
1~_K _______  
'10 b 
": 5 .... 
e_. : --- _---;! 
l 5 6 1 i 9 1;-J J1f'u-O 
2·-
1.5 '- -
g 
co 
~ 1,. -
S .-.. 
~ . a_ 
DAn POI' ,.,..........,. 
. 
PATIENT IZ 
pi .. ".. 
0.5 !- • _ -
--20 
PATlENTGB 
6 P-- 10 
5 -' , : 8 
-S4- "/- - ,6 t ' ,3 _ 
. .\ § . ,4 
if2L 
--
- "',- -
. . 
--------------------
4 -'-. 
3.5 ~ 
3 • 
-S 2.5 : 
'" . ~ 2. 
" 1,5 • 
IL 
o 
1 '... • ..• 
0.5 ~:-
PATJENTL T 
plaeme 
3 
. -~K 
---'- -- 40 
~ '. 
5 6' i Ii 9 10 1; 12 13 0 
CAY.ItO_' TRANIPUNT 
;;i 
1" 
::i. 
iili 
i 
:J 
iii 
..J C I 
.... 
01 
..... 
FIG. 3. Plasma FK 506 concentrations as measured by Sep-Pak enzyme-linked immunosorbent assay (ELISA) (triangles). methylene 
chloride ELISA (black boxes). high-periormance liquid chromatography ELISA (circles) and bilirubin (white boxes) in four liver 
transplant patients. 
is the predominant species in the whole blood and 
that relatively few metabolites accumulate in the 
blood. While similar correlation (0.786) has been 
reported for blood tacrolimus concentrations mea-
sured by SP-ELISA and MC-ELISA. lower slopes 
indicative of actual differences between these mea-
surements have been reported (5.15). Our observa-
tions with regard to tacrolimus are consistent with 
the fact that little or no tacrolimus equivalent could 
be measured in fraction I. collected on the HPLC. 
Whether the lack of tacrolimus equivalents in frac-
tion I is due to the absence of cross-reacting tac-
rolimus metabolites in this fraction or to the poten-
tial instability of any tacrolimus metabolites in this 
fraction during the experimental procedure cannot 
now be clarified. 
We have also noted the blood concentration of 
tacrolimus to be consistently higher loverall mean 
:t SD blood-to-plasma ratio (B/P) was 12.8 :t 8.4: 
for kidney transplant patients. B/P was 16.8 :!: 9.9: 
for liver transplant patients. B/P was 9.8 ± 5.51 than 
the corresponding plasma concentrations in all the 
patients observed at all times. as has been reported 
Thu Drull Mm,;,. Vol. 17. No.2. 1995 
earlier (2.6-8.10.13.15). These observations along 
with our earlier report would suggest that the parent 
tacrolimus is the primary species in the red blood 
cell and that tacrolimus metabolites do not appre-
ciably partition into the red blood cells. The actual 
concentration of the metabolites that tend to accu-
mulate in the plasma of patients with liver dysfunc-
tion appears to be very small compared to the total 
concentration of tacrolimus in the whole blood. Our 
conclusions differ from those of the recent publica-
tion (15). which suggests that the whole blood SP-
ELISA and MC-ELISA are nonspecific and simul-
taneously measure tacrolimus metabolites as well. 
While these investigators showed some (10-15%) 
cross-reactivity of one of the metabolites (di-
methyl hydroxy tacrolimus). three other metabo-
lites tested did not show any appreciable cross-
reactivity with the monoclonal antibody used in the 
ELISA procedure. These investigators also inter-
preted increased tacrolimus concentrations during 
episodes of liver dysfunction to be due to accumu-
lation of tacrolimus metabolites. It should be real-
ized that increased tacrolimus concentrations dur-
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FIG. 4. Plasma FK 506 concentrations as measured by Sep·Pak enzyme·linked immunosorbent assay (ELISA) (triangles). methylene 
chloride ELISA (black boxes). high·performance liquid chromatography ELISA (circles). and creatinine (white boxes) In four kidney 
transplant patients. 
ing episodes of rejection could very well be the reo 
suit of impaired tacrolimus metabolism and 
accumulation of unchanged tacrolimus. 
plasma concentrations. This is consistent with pub-
lished data (9.15). It is also of interest to note that 
the slopes of the lines describing the whole blood-
to-plasma concentration of tacrolimus were 4.1 and 
II. 7. respectivel v. in liver and kidney transplant pa-
tients (Fig. 5). When only HPLC-ELISA data were 
We have observed an overall poor correlation (r 
=: 0.44 in liver and 0.4 in kidney transplant patients. 
respectively) between the trough blood and trough 
FIG. S. Correlation between whole blood and 
plasma as measured by solid phase extraction. 
liquid extraction. and high·performance liquid 
,hromatography (HPLCl (circles/. In four kidney 
transplant pallents. Correlations between whole 
111000 and plasma as measured by solid phase c:x· 
traction and liquid extraction (boxes) and by 
IIPLC (triangles) In four liver transplant patients. 
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TABLE 4. FK506-whole blood vs. plasma correlation 
analysis as measured by different methods 
Slope Intercept r No. 
Liver transplant 
Sep-pak ELISA 4.0 3.5 0.52 58 
methylene chloride ELISA 4.1 4.7 0.47 58 
HPLC ELISA 7.7 3.9 0.59 36 
overall (all three methods) ·U 4.9 0.44 152 
Kidney transplant 
Sep-pak ELISA 11.3 7.0 0.50 43 
methylene chloride ELISA 12.2 7.5 0.31 37 
HPLC ELISA 11.9 7.4 0.44 38 
overall (all three methods) 11.7 7.4 0.4 118 
ELISA. enzyme-linked immunosorbent assay: HPLC, high-
performance liquid chromatography. 
compared, the slopes were 7.7 and 11.9, respec-
tively, in liver and kidney transplant patients. Our 
observations in kidney transplant patients indicate 
that the metabolites of tacrolimus do not accumu-
late in plasma and/or that they are removed by the 
extraction process used. 
Our observations in the liver transplant patients 
can be partly explained by the accumulation and 
simultaneous quantitation of some ELISA cross-
reactive metabolites of tacrolimus by SP-ELISA 
and MC-ELISA in plasma obtained from liver 
transplant patients with poor liver function. The 
higher slope of the blood-to-plasma concentration 
comparison, 11.7 and 7.7. respectively, in kidney 
and liver transplant patients suggests higher uptake/ 
binding of tacrolimus to the red blood cells or de-
creased plasma protein binding of tacrolimus in kid-
ney transplant patients as compared to liver trans-
plant patients. 
The significant positive intercept U.S to 7.5) ob-
served is similar to what has been observed earlier 
(6,8,15) and is consistent with the reported nonlin-
ear uptake of tacrolimus by the red blood cells (6,8). 
These observations indicate that it is inappropriate 
to extrapolate blood tacrolimus concentrations 
based on plasma tacrolimus concentration measure-
ments made in transplant patients. 
Our current observations are also consistent with 
our previous report that the concentrations of tac-
rolimus as measured by the three methods are also 
independent of the route of administration of tac-
rolimus ( 10). Tacrolimus is known to be metabolized 
by the cytochrome P-450 enzyme system (20-22), 
and this enzyme system is known to be present in 
the gut. In vitro studies with gut cytochrome P-450 
(unpublished observations I provide indirect evi-
dence of the involvement of gut metabolism in tac-
T/,u Drult M"fI". ~D"fK 17. No.2. 1995 
rolimus disposition. It is possible that in this patient 
population there was no route-dependent metabo-
lism of tacrolimus, or that the metabolites produced 
in the gut do not cross-react with the monoclonal 
antibody used in this assay. or metabolites formed 
in the gut are removed during the extraction pro-
cess. 
Our study indicates that tacrolimus can be mea-
sured in whole blood by ELISA after SP or meth-
ylene chloride extraction. The trough blood concen-
trations of tacrolimus are seven to 12 times as high 
as the corresponding plasma concentrations. The 
blood-to-plasma ratio of tacrolimus is dependent on 
the assay method used. the nature of the organ 
transplanted. and the functional status of the liver. 
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